Incremental US regulatory approvals will boost growth of large-cap domestic drug players. In the recent years domestic pharma companies have been hurt by issues such as pricing pressures in the US, FDA regulatory hurdles and more recently allegations of price collusions. But easing of FDA troubles should provide momentum and support to valuations of such stocks going forward.
Get us on https://www.linkedin.com/title/ripples-advisory click here, more and for Two days Free Trial drop your missed call on -9303093093 
No comments:
Post a Comment